Chang Tan

Dr. Chang Tan

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
CTChang Tan
Chang Tan
QWQian-Qian Wang
Qian-Qian Wang
YZYuanchen Zhou
Yuanchen Zhou
GQGeng Qin
Geng Qin
SYShu-Kun Yao
Shu-Kun Yao
Background Advanced colorectal adenomas are precancerous lesions of colorectal cancer (CRC), and early screening and diagnosis are highly important for improving patient prognosis. However, traditional blood tumor markers have poor diagnostic efficacy for advanced adenoma (AA) and early-stage CRC. Methods We collected serum samples from normal controls, AA patients, and CRC patients (before and 48 h after surgery). Using the enzyme-linked immunosorbent assay method, we compared the serum lipopolysaccharide-binding protein (LBP) and vasodilator-stimulated phosphoprotein (VASP) levels among the three groups. Additionally, we analyzed and compared the serum LBP and VASP levels with the clinicopathological features of the tumors. Finally, we plotted receiver operating characteristic curves, calculated the area under curve and cutoff points, and evaluated the diagnostic efficacy of serum LBP and VASP for AA and CRC patients. Results Serum LBP and VASP levels were significantly greater in patients with AA and CRC than in healthy controls, and decreased significantly postoperatively compared with preoperatively. Compared with clinicopathological features, serum LBP levels were significantly greater in patients with severe dysplasia in adenomas, whereas serum VASP levels were significantly greater in patients with larger tumors, advanced stages, poorer tumor differentiation, and KRAS gene mutations. Compared with traditional tumor markers, serum LBP and VASP demonstrate good diagnostic efficacy for AA and CRC. Conclusion Our study innovatively proposes that the serum LBP and VASP proteins could serve as potential novel biomarkers for noninvasive screening of colorectal tumors, with better diagnostic efficacy than traditional blood tumor markers.